Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources

Tue Jun 28, 2011 10:04am EDT

* Reuters is not responsible for the content in this press release.

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources

PR Newswire

PARSIPPANY, N.J., June 28, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI) announced today that Danesha Dixon Smith has joined the company as its Vice President of Human Resources.

"Hiring and developing results-driven employees who are passionate about their work and committed to patients -- our ultimate customers -- is a priority for our organization," said John P. Gargiulo, President and Chief Executive Officer of Daiichi Sankyo, Inc. "We believe every employee has a direct impact on the success of the organization and we are excited to have Danesha on our team.  She has a proven track record of recruitment and talent development, and will integrate these principles into our overall business strategy."

Ms. Dixon Smith brings more than 10 years of human resource leadership to DSI having worked at Fortune 500 companies such as the Home Depot and Realogy (formerly Cendant), as well as global brands such as Kenneth Cole Productions, Inc., and Liz Claiborne, Inc.

"I am excited to help DSI continue to build its reputation as a great place to work," said Ms. Dixon Smith.  "The company takes employee performance, accountability and integrity very seriously and I'm looking forward to joining the executive leadership team, as well as my HR team, to guide the company through its next stage of growth and success."

Ms. Dixon Smith received a Bachelor of Arts in Business Administration from Clark Atlanta University, and a Master of Arts in Human Resources Management from Keller Graduate School of Management, also in Atlanta, Georgia.  

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group.  For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.

SOURCE Daiichi Sankyo, Inc.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.